Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $11.12 for the day, up 8.49% from the previous closing price of $10.25. In other words, the price has increased by $8.49 from its previous closing price. On the day, 6.6 million shares were traded. NTLA stock price reached its highest trading level at $11.47 during the session, while it also had its lowest trading level at $10.3209.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 01 ’25 when Clark Eliana sold 1,022 shares for $9.82 per share. The transaction valued at 10,036 led to the insider holds 95,369 shares of the business.
Dube Michael P sold 2,503 shares of NTLA for $24,905 on Jul 02 ’25. The VP, Chief Accounting Officer now owns 57,137 shares after completing the transaction at $9.95 per share. On Jun 30 ’25, another insider, GOODMAN JESSE, who serves as the Director of the company, sold 1,547 shares for $9.56 each. As a result, the insider received 14,789 and left with 25,906 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1151842944 and an Enterprise Value of 587118208. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.28 while its Price-to-Book (P/B) ratio in mrq is 1.48. Its current Enterprise Value per Revenue stands at 12.884 whereas that against EBITDA is -1.106.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.29, which has changed by -0.5196544 over the last 52 weeks, in comparison to a change of 0.10500872 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 26.70%, while the 200-Day Moving Average is calculated to be -5.75%.
Shares Statistics:
NTLA traded an average of 4.44M shares per day over the past three months and 4408620 shares per day over the past ten days. A total of 103.54M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.95% of the company’s shares, while institutions hold 92.31% stake in the company. Shares short for NTLA as of 1749772800 were 29689496 with a Short Ratio of 6.68, compared to 1747267200 on 30704048. Therefore, it implies a Short% of Shares Outstanding of 29689496 and a Short% of Float of 32.630002000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
